Liraglutide improves the rate of achieving composite outcome in patients with type 2 diabetes
10.3760/cma.j.issn.1000-6699.2012.07.022
- VernacularTitle:利拉鲁肽提高2型糖尿病患者复合终点达标率
- Author:
Jumin LU
- Publication Type:Journal Article
- Keywords:
Diabetes mellitus,type 2;
Incretin;
Glucagon-like peptide-1;
Liraglutide
- From:
Chinese Journal of Endocrinology and Metabolism
2012;28(7):609-612
- CountryChina
- Language:Chinese
-
Abstract:
Suboptimal hyperglycemia control,side effects of traditional anti-diabetic agents such as hypoglycemia and weight gain are problems in current treatment for type 2 diabetes.Type 2 diabetes is a complex systemic metabolic disorder,which makes composite outcome measurement a new recommendation in diabetes guidelines.Besides a good glycaemic control,glucagon like peptide-1 analogue liraglutide also has the effects of weight reduction,lowering blood pressure and improvement on β cell function with lower risk of hypoglycemia.Liraglutide Phase Ⅲ clinical trials and meta-analyses confirmed its unique advantages of multiple effects and higher odds of achieving composite outcome,suggesting the potential of liraglutide to improve the overall prognosis of patients with type 2 diabetes.
